PMID- 33620515
OWN - NLM
STAT- MEDLINE
DCOM- 20220111
LR  - 20220111
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Print)
IS  - 0172-8172 (Linking)
VI  - 41
IP  - 7
DP  - 2021 Jul
TI  - Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a 
      case-based review.
PG  - 1357-1367
LID - 10.1007/s00296-021-04810-w [doi]
AB  - Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are systemic 
      necrotizing vasculitides associated with significant morbidity and mortality. 
      Given the immunosuppression used to manage these conditions, it is important for 
      clinicians to recognize complications, especially infectious ones, which may 
      arise during treatment. Kaposi sarcoma (KS) is a lymphoangioproliferative 
      neoplasm caused by human herpes virus 8 (HHV-8). Its cutaneous manifestations can 
      mimic vasculitis. We describe a 77-year-old man with microscopic polyangiitis 
      with pulmonary-renal syndrome treated with prednisone and intravenous 
      cyclophosphamide who developed KS (HHV-8 positive) after 2 months of treatment. 
      Cyclophosphamide was discontinued and prednisone gradually lowered with 
      improvement and clinical stabilization of KS lesions. This comprehensive review 
      includes all published cases of KS in patients with AAV, with a goal to summarize 
      potential risk factors including the clinical characteristics of vasculitis, 
      treatment and outcomes of patients with this rare complication of 
      immunosuppressive therapy. We also expanded our literature review to KS in other 
      forms of systemic vasculitis. Our case-based review emphasizes the importance of 
      considering infectious complications of immunosuppressive therapy, especially 
      glucocorticoids, and highlights the rare association of KS in systemic 
      vasculitis.
FAU - Tiong, Benedict K
AU  - Tiong BK
AUID- ORCID: 0000-0001-5556-3335
AD  - Division of Rheumatology, David Geffen School of Medicine, University of 
      California, Los Angeles, 2020 Santa Monica Boulevard, Suite 540, Santa Monica, 
      CA, 90404, USA. BTiong@mednet.ucla.edu.
FAU - Singh, Arun S
AU  - Singh AS
AD  - Division of Hematology and Oncology, David Geffen School of Medicine, University 
      of California, Los Angeles, Los Angeles, CA, USA.
FAU - Sarantopoulos, G Peter
AU  - Sarantopoulos GP
AD  - Department of Pathology and Laboratory Medicine, UCLA Medical Center, David 
      Geffen School of Medicine, University of California, Los Angeles, Los Angeles, 
      CA, USA.
FAU - Kermani, Tanaz A
AU  - Kermani TA
AUID- ORCID: 0000-0002-7335-7321
AD  - Division of Rheumatology, David Geffen School of Medicine, University of 
      California, Los Angeles, 2020 Santa Monica Boulevard, Suite 540, Santa Monica, 
      CA, 90404, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20210223
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Aged
MH  - Cyclophosphamide/*therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Male
MH  - Microscopic Polyangiitis/*complications/drug therapy/pathology
MH  - Prednisone/*therapeutic use
MH  - Remission Induction
MH  - Sarcoma, Kaposi/*complications/pathology
PMC - PMC8164621
OTO - NOTNLM
OT  - Anti-neutrophil cytoplasmic antibody-associated vasculitis
OT  - Granulomatosis with polyangiitis
OT  - Kaposi sarcoma
OT  - Microscopic polyangiitis
OT  - Prednisone
OT  - Vasculitis
COIS- The authors declare that they have no conflicts of interest/competing interests.
EDAT- 2021/02/24 06:00
MHDA- 2022/01/12 06:00
PMCR- 2021/02/23
CRDT- 2021/02/23 12:15
PHST- 2020/12/08 00:00 [received]
PHST- 2021/02/06 00:00 [accepted]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2022/01/12 06:00 [medline]
PHST- 2021/02/23 12:15 [entrez]
PHST- 2021/02/23 00:00 [pmc-release]
AID - 10.1007/s00296-021-04810-w [pii]
AID - 4810 [pii]
AID - 10.1007/s00296-021-04810-w [doi]
PST - ppublish
SO  - Rheumatol Int. 2021 Jul;41(7):1357-1367. doi: 10.1007/s00296-021-04810-w. Epub 
      2021 Feb 23.